The Food and Drug Administration has cleared a blood test that can help doctors decide whether a patient's memory problems are being driven by Alzheimer's disease, without first sending that patient for a brain scan or a spinal tap.
Roche announced the clearance of its Elecsys pTau217 plasma test on August 24, 2026, for use in adults 55 and older who already have signs, symptoms, or complaints of cognitive decline. The test was developed with Eli Lilly and Company.
